What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
Identifieur interne : 003585 ( PubMed/Checkpoint ); précédent : 003584; suivant : 003586What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
Auteurs : Stephen J. KishSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- Brain (blood supply), Brain (drug effects), Brain (physiopathology), Carrier Proteins (drug effects), Hallucinogens (adverse effects), Humans, Membrane Glycoproteins (drug effects), Membrane Transport Proteins, N-Methyl-3,4-methylenedioxyamphetamine (adverse effects), Nerve Tissue Proteins, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Parkinson Disease, Secondary (physiopathology), Receptors, Dopamine (drug effects), Serotonin Plasma Membrane Transport Proteins, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , adverse effects : Hallucinogens, N-Methyl-3,4-methylenedioxyamphetamine.
- chemical , drug effects : Carrier Proteins, Membrane Glycoproteins, Receptors, Dopamine.
- blood supply : Brain.
- chemically induced : Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Secondary.
- drug effects : Brain.
- physiopathology : Brain, Parkinson Disease, Secondary.
- Humans, Membrane Transport Proteins, Nerve Tissue Proteins, Serotonin Plasma Membrane Transport Proteins, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon.
DOI: 10.1002/mds.10643
PubMed: 14639660
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:14639660Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?</title><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14639660</idno><idno type="pmid">14639660</idno><idno type="doi">10.1002/mds.10643</idno><idno type="wicri:Area/PubMed/Corpus">003649</idno><idno type="wicri:Area/PubMed/Curation">003649</idno><idno type="wicri:Area/PubMed/Checkpoint">003585</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?</title><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brain (blood supply)</term><term>Brain (drug effects)</term><term>Brain (physiopathology)</term><term>Carrier Proteins (drug effects)</term><term>Hallucinogens (adverse effects)</term><term>Humans</term><term>Membrane Glycoproteins (drug effects)</term><term>Membrane Transport Proteins</term><term>N-Methyl-3,4-methylenedioxyamphetamine (adverse effects)</term><term>Nerve Tissue Proteins</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (diagnosis)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Receptors, Dopamine (drug effects)</term><term>Serotonin Plasma Membrane Transport Proteins</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hallucinogens</term><term>N-Methyl-3,4-methylenedioxyamphetamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Carrier Proteins</term><term>Membrane Glycoproteins</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Membrane Transport Proteins</term><term>Nerve Tissue Proteins</term><term>Serotonin Plasma Membrane Transport Proteins</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">14639660</PMID><DateCreated><Year>2003</Year><Month>11</Month><Day>25</Day></DateCreated><DateCompleted><Year>2004</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2003</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?</ArticleTitle><Pagination><MedlinePgn>1219-23</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kish</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>KE1SEN21RM</RegistryNumber><NameOfSubstance UI="D018817">N-Methyl-3,4-methylenedioxyamphetamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Mov Disord. 2003 Nov;18(11):1378-81</RefSource><PMID Version="1">14639685</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006213">Hallucinogens</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008562">Membrane Glycoproteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D026901">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018817">N-Methyl-3,4-methylenedioxyamphetamine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009419">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050486">Serotonin Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014055">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>27</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14639660</ArticleId><ArticleId IdType="doi">10.1002/mds.10643</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003585 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003585 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:14639660
|texte= What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:14639660" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |